NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

LC,

Did you mention “truth” in that post? 😶

Thanks for posting, but I think that we should seek trustworthy advice from licensed oncologists. I ran your statement through the detector…




“This statement is misleading and unreliable for several reasons:

1. **Lack of Credibility**: The author's anonymity and lack of credentials as an oncologist mean they likely don't have the expertise to accurately assess the efficacy of a cancer treatment like DCVax-L. Expert medical opinions typically come from qualified healthcare professionals.

2. **Generalized and Unsupported Claims**: The claim that DCVax-L is only "mildly effective in some small subset of patients" is a broad generalization without supporting data. Clinical effectiveness should be backed by scientific studies and clinical trial results.

3. **Misrepresentation of Treatment Protocol**: Suggesting that DCVax-L "requires brutal chemo and radiation up front" is misleading. DCVax-L is a type of immunotherapy, and while it might be used in conjunction with chemotherapy and radiation, describing these as "brutal" is subjective and doesn't accurately represent the nuanced decision-making in cancer treatment protocols.

4. **Dismissive Tone**: The statement's dismissive tone ("But don't let the truth get in your way") undermines its reliability. It suggests a biased viewpoint rather than a balanced, evidence-based assessment.

Additionally, the statement fails to acknowledge the potential of DCVax-L for use in combination therapy beyond traditional chemotherapy and radiation. Recent trends in cancer treatment show a growing interest in combining different therapeutic modalities, including immunotherapies like DCVax-L with other agents such as PD-1 blockade. These combination therapies can potentially enhance overall efficacy and provide new treatment avenues for patients. The dismissive tone of the statement overlooks these evolving and nuanced approaches in oncology, further undermining its reliability.

In summary, the statement's lack of credible authorship, generalized claims, and subjective language make it misleading and unreliable as a source of information about DCVax-L or any medical treatment.”

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847